EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer

Takafumi Nakano, Seiichiro Takao, Katsushi Dairaku, Naoki Uno, Siew-Kee Amanda Low iD, Masahiro Hashimoto iD, Yasuo Tsuda, Yuichi Hisamatsu, Takeo Toshima iD, Yusuke Yonemura, Takaaki Masuda iD, Ken Eto und 5 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Takafumi Nakano und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Neoplasm, Residual, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: OITA Cancer Research Foundation, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Considering the cost and invasiveness of monitoring postoperative minimal residual disease (MRD) of colorectal cancer (CRC) after adjuvant chemoradiotherapy (ACT), we developed a favorable approach based on methylated circulating tumor DNA to detect MRD after radical resection. Analyzing the public database, we identified the methylated promoter regions of the genes FGD5 , GPC6 , and MSC . Using digital polymerase chain reaction (dPCR), we termed the “amplicon of methylated sites using a specific enzyme” assay as “AMUSE.” We examined 180 and 114 pre‐ and postoperative serial plasma samples from 28 recurrent and 19 recurrence‐free pathological stage III CRC patients, respectively. The results showed 22 AMUSE‐positive of 28 recurrent patients (sensitivity, 78.6%) and 17 AMUSE‐negative of 19 recurrence‐free patients (specificity, 89.5%). AMUSE predicted recurrence 208 days before conventional diagnosis using radiological imaging. Regarding ACT evaluation by the reactive response, 19 AMUSE‐positive patients during their second or third blood samples showed a significantly poorer prognosis than the other patients ( p = 9E‐04). The AMUSE assay stratified four groups by the altered patterns of tumor burden postoperatively. Interestingly, only 34.8% of cases tested AMUSE‐negative during ACT treatment, indicating eligibility for ACT. The AMUSE assay addresses the clinical need for accurate MRD monitoring with universal applicability, minimal invasiveness, and cost‐effectiveness, thereby enabling the timely detection of recurrences. This assay can effectively evaluate the efficacy of ACT in patients with stage III CRC following curative resection. Our study strongly recommends reevaluating the clinical application of ACT using the AMUSE assay.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsNeoplasm, ResidualNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedDNA MethylationCirculating Tumor DNAPrognosisChemoradiotherapy, AdjuvantPromoter Regions, GeneticBiomarkers, TumorAdultNeoplasm StagingAged, 80 and overPolymerase Chain Reaction

Stichwörter der Autor:innen

DNA methylationdrug resistancegene expression analysistumor biomarker

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
  • Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Department of Colorectal Surgery, Gastroenterological Cancer Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

ORCID-Profile: Siew-Kee Amanda Low, Masahiro Hashimoto, Takeo Toshima, Takaaki Masuda, Satoshi Nagayama, Koshi Mimori

Förderung

  • OITA Cancer Research Foundation
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Takeda Science Foundation
  • Princess Takamatsu Cancer Research Fund

Zitieren

APA

Nakano, T., Takao, S., Dairaku, K., Uno, N., Low, S. A., Hashimoto, M., Tsuda, Y., Hisamatsu, Y., Toshima, T., Yonemura, Y., Masuda, T., Eto, K., Ikegami, T., Fukunaga, Y., Niida, A., Nagayama, S., & Mimori, K. (2024). Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer. Cancer Science. https://doi.org/10.1111/cas.16149

Vancouver

Nakano T, Takao S, Dairaku K, Uno N, Low SA, Hashimoto M, et al. Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer. Cancer Science. 2024. doi:10.1111/cas.16149

BibTeX
@article{Nakano2024,
  author = {Nakano, Takafumi and Takao, Seiichiro and Dairaku, Katsushi and Uno, Naoki and Low, Siew-Kee Amanda and Hashimoto, Masahiro and Tsuda, Yasuo and Hisamatsu, Yuichi and Toshima, Takeo and Yonemura, Yusuke and Masuda, Takaaki and Eto, Ken and Ikegami, Toru and Fukunaga, Yosuke and Niida, Atsushi and Nagayama, Satoshi and Mimori, Koshi},
  title = {Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16149}
}
Kostenlos starten →